EC Number | Application | Comment | Organism |
---|---|---|---|
2.1.1.63 | medicine | combining cisplatin and temozolomide is based on the potential for improved antitumour activity, combination is well tolerated in children and adolescents, generating no toxicity greater than that of the single agents | Homo sapiens |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
2.1.1.63 | temozolomide | treatment for 5 days depletes MGMT in peripheral mononuclear cells in at least 76% of patients and low MGMT activity is correlated with severe thrombocytopenia during the first treatment cycle | Homo sapiens |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.1.1.63 | Homo sapiens | - |
- |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
2.1.1.63 | PBMC cell line | - |
Homo sapiens | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.1.1.63 | DNA containing 6-O-methylguanine + [protein]-L-cysteine | - |
Homo sapiens | DNA lacking 6-O-methylguanine + [protein]-S-methyl-L-cysteine | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
2.1.1.63 | MGMT | - |
Homo sapiens |
2.1.1.63 | O6-alkylguanine-DNA alkyltransferase | - |
Homo sapiens |